Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients

Cell Mol Immunol. 2015 Jan;12(1):122-4. doi: 10.1038/cmi.2014.27. Epub 2014 Jun 2.

Authors

Matteo Santoni¹, Francesco Massari², Stefano Cascinu¹

Affiliations

¹ Clinica di Oncologia Medica, AOU Ospedali Riuniti, Università Politecnica delle Marche, Ancona, Italy.
² Medical Oncology, 'G.B. Rossi' Academic Hospital, University of Verona, Verona, Italy.

No abstract available

Publication types

Letter
Review

MeSH terms

Animals
CD18 Antigens / metabolism
Cardiovascular Diseases / etiology
Cardiovascular Diseases / prevention & control*
Cell Adhesion / drug effects
Coronary Vessels / drug effects*
Coronary Vessels / pathology
Cytokines / metabolism
Everolimus
Graft Rejection / etiology
Graft Rejection / prevention & control*
Heart Transplantation*
Humans
Immunosuppressive Agents / therapeutic use*
Inflammation Mediators / metabolism
Neutrophils / drug effects*
Neutrophils / immunology
Postoperative Complications / prevention & control*
Sirolimus / analogs & derivatives*
Sirolimus / pharmacology
Sirolimus / therapeutic use
TOR Serine-Threonine Kinases / antagonists & inhibitors

Substances

CD18 Antigens
Cytokines
Immunosuppressive Agents
Inflammation Mediators
Everolimus
TOR Serine-Threonine Kinases
Sirolimus